We recently published 10 Stocks Leaving Wall Street in the Dust; 4 Hit Fresh Records. ImmunityBio Inc. (NASDAQ:IBRX) was one of the top performers on Tuesday. ImmunityBio extended its winning streak ...

ImmunityBio Inc. (NASDAQ:IBRX) is one of the 13 hot stocks to buy with the highest upside potential. On February 2, ImmunityBio Inc. (NASDAQ:IBRX) announced that it has initiated a Phase 2 clinical ...

ImmunityBio Inc IBRX shares were up during Monday’s premarket session, but dipped as the company addresses compliance issues ...

In the past week, the United States market has experienced a 3.5% increase and boasts a remarkable 31% rise over the last year, with earnings projected to grow by 16% annually. In such an environment, ...

ImmunityBio, Inc. (NASDAQ:IBRX) is one of the 10 Best Performing Stocks of Q1 2026 to Watch for Q2. On March 24, BTIG maintained its Buy rating on ImmunityBio, Inc. (NASDAQ:IBRX) with a price target ...

Enrollment of BCG naïve subjects (QUILT-2.005) receiving BCG alone versus BCG plus ANKTIVA exceeding expectations 85% enrolled with anticipated completion in Q2 2026 with BLA filing to U.S. Food and ...

Durable complete responses with CAR-NK + Rituximab in patients who failed current standards of care in Waldenstrom’s Non-Hodgkins lymphoma (NHL). Long-term evaluable patients demonstrate ongoing ...

Shares of cancer and infectious disease therapy developer ImmunityBio, Inc. (NASDAQ: IBRX), spiked 34% higher as of 1 p.m. ET on Friday and are now up a staggering 127% this week after an incredible ...

CULVER CITY, Calif.--(BUSINESS WIRE)-- ImmunityBio, Inc. (NASDAQ: IBRX), a clinical-stage immunotherapy company, today announced that it recently held a Type B End-of-Phase meeting with the U.S. FDA ...

Recommendation is based on peer-reviewed clinical data supporting long-term effectiveness and safety durability in patients with papillary-only disease treated with ANKTIVA plus BCG1. CULVER CITY, ...